S. Stintzing

发表

The influence of KRAS and BRAF mutations on the efficacy of cetuximab‐based first‐line therapy of metastatic colorectal cancer: An analysis of the AIO KRK‐0104‐trial

C. Giessen, C. Schulz, M. Haas, 2012, International journal of cancer.

Reconsidering the benefit of intermittent versus continuous treatment in the maintenance treatment setting of metastatic colorectal cancer.

T. Bekaii-Saab, S. Stintzing, Y. Sunakawa, 2016, Cancer treatment reviews.

Variations in genes involved in immune response checkpoints and association with outcomes in patients with resected colorectal liver metastases

T. Gruenberger, H. Lenz, W. Zhang, 2015, The Pharmacogenomics Journal.

Variations in genes involved in dormancy associated with outcome in patients with resected colorectal liver metastases.

T. Gruenberger, A. Barzi, H. Lenz, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Variations in Genes Involved in Dormancy Associated with Outcome in Patients with Resected Colorectal Liver Metastases Original Articles Annals of Oncology

T. Gruenberger, A. Barzi, H. Lenz, 2022 .

Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study.

A. Kiani, S. Al-Batran, T. Kirchner, 2017, European journal of cancer.

CXCR4 polymorphism predicts progression-free survival in metastatic colorectal cancer patients treated with first-line bevacizumab-based chemotherapy

H. Lenz, W. Zhang, S. Okazaki, 2016, The Pharmacogenomics Journal.

Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials.

H. Lenz, V. Heinemann, W. Zhang, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Title: Clinical significance of TLR1 I602S polymorphism for patients with metastatic colorectal cancer treated with FOLFIRI plus bevacizumab

H. Lenz, S. Okazaki, Dongyun Yang, 2016 .

Resection of Pulmonary Metastases from Colon and Rectal Cancer: Factors to Predict Survival Differ Regarding to the Origin of the Primary Tumor

A. Crispin, M. Stemmler, V. Heinemann, 2014, Annals of Surgical Oncology.

Prognostic and predictive impact of metastatic organ involvement on maintenance therapy in advanced metastatic colorectal cancer: Subgroup analysis of patients treated within the PanaMa trial (AIO KRK 0212)

T. Trarbach, S. Haas, E. Goekkurt, 2023, International journal of cancer.

A study-level meta-analysis of efﬁcacy data from head-to-head ﬁrst-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer

J. Douillard, J. Terwey, R. Koukakis, 2022 .

KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer

V. Heinemann, A. Jung, R. Laubender, 2013, Journal of Cancer Research and Clinical Oncology.

Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer

H. Lenz, W. Zhang, S. Scherer, 2014, The Pharmacogenomics Journal.

Next-Generation CEA-CAR-NK-92 Cells against Solid Tumors: Overcoming Tumor Microenvironment Challenges in Colorectal Cancer

A. S. Franzén, Clarissa Radecke, Abdelhadi Boulifa, 2024, Cancers.

Molecular testing and liquid biopsies in colorectal cancer

A. Stahler, S. Stintzing, 2024, Die Gastroenterologie.

FOLFOX plus panitumumab or FOLFOX alone as additive therapy following R0/1 resection of RAS wild-type colorectal cancer liver metastases - The PARLIM trial (AIO KRK 0314).

K. Kaczirek, A. Kiani, M. Karthaus, 2022, European journal of cancer.